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Abstract
Genetic variation in the leucine-rich repeat and Ig domain containing 1 gene (LINGO1) was
recently associated with an increased risk of developing essential tremor (ET) and Parkinson
disease (PD). Herein, we performed a comprehensive study of LINGO1 and its paralog LINGO2 in
ET and PD by sequencing both genes in patients (ET, n=95; PD, n=96) and by examining
haplotype-tagging single-nucleotide polymorphisms (tSNPs) in a multicenter North American
series of patients (ET, n=1,247; PD, n=633) and controls (n=642). The sequencing study identified
six novel coding variants in LINGO1 (p.S4C, p.V107M, p.A277T, p.R423R, p.G537A, p.D610D)
and three in LINGO2 (p.D135D, p.P217P, p.V565V), however segregation analysis did not
support pathogenicity. The association study employed 16 tSNPs at the LINGO1 locus and 21 at
the LINGO2 locus. One variant in LINGO1 (rs9652490) displayed evidence of an association with
ET (odds ratio (OR)=0.63; P=0.026) and PD (OR=0.54; P=0.016). Additionally, four other tSNPs
in LINGO1 and one in LINGO2 were associated with ET and one tSNP in LINGO2 associated
with PD (P<0.05). Further analysis identified one tSNP in LINGO1 and two in LINGO2 which
influenced age at onset of ET and two tSNPs in LINGO1 which altered age at onset of PD
(P<0.05). Our results support a role for LINGO1 and LINGO2 in determining risk for and perhaps
age at onset of ET and PD. Further studies are warranted to confirm these findings and to
determine the pathogenic mechanisms involved.
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Introduction
Essential tremor (ET) and Parkinson disease (PD) are prevalent age-related movement
disorders affecting about 3–6% (ET) and 1–2% of individuals over the age of 65 years (PD)
[1–4]. While both ET and PD may cause significant motor impairment with tremor, they are
regarded as distinct entities based on major differences at the clinical and pathological
levels. ET patients display mostly symmetric action tremor which contrasts with asymmetric
PD tremor that occurs at rest and is associated with bradykinesia, rigidity, and postural
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instability. Pathologically, some ET cases have Purkinje cell loss and Purkinje cell axonal
dilations (torpedoes) in the cerebellum [5]. Some cases have α-synuclein immunopositive
Lewy bodies (LB) in the brainstem [5]. Conversely, in PD there is severe neuronal loss in
brainstem nuclei with abundant LB pathology [5, 6]. Despite these differences, clinical
evidence indicates an overlap exists between ET and PD with a fourfold increased risk of
PD in patients with ET, increased prevalence of ET in relatives of patients with PD and the
presence of action tremor often preceding the onset of PD symptoms [7]. Furthermore,
imaging studies found signs of dopaminergic deficiency in some ET patients and brainstem
LB have been reported in ET cases [8].
The leucine-rich repeat and Ig domain containing 1 gene (LINGO1) has recently been
associated with an increased risk of developing ET and PD, providing the first evidence of a
genetic link between the two diseases [9]. LINGO1 is a central nervous system-specific
component of the Nogo-66 receptor (NgR1)/p75/LINGO1 signaling complex implicated in
inhibition of oligodendrocyte differentiation, axonal myelination and regeneration, and
neuronal survival [10–16]. Expression of LINGO1 is increased after neuronal damage or cell
death and its inhibition promotes functional recovery and axonal sprouting after spinal cord
injury [10, 14, 17]. The expression of LINGO1 is higher in the substantia nigra of patients
with PD compared to age-matched controls and increases in ventral midbrain neurons in
animal models of PD after neurotoxic lesions [10]. Furthermore, reduction of LINGO1
activity was shown to improve survival, growth, and function of dopaminergic neurons both
in primary cell cultures and in vivo experimental models of parkinsonism in rodents [10,
18]. These data highlight the functional relevance of LINGO1 as a regulator of neuronal
death, which is consistent with LINGO1 variability altering the risk for ET and PD [9, 19,
20].
The leucine-rich repeat and Ig domain containing 2 gene (LINGO2) is a much less well
characterized paralog of LINGO1. In contrast to the other LINGO1 paralogs (LINGO3 and
LINGO4), LINGO2 expression is detectable in the mouse adult brain and appears to be
restricted to neuronal tissue [21, 22]. We recently performed a genome-wide association
study in a PD patient-control series that identified single-nucleotide polymorphisms (SNPs)
in SNCA and LRRK2 associated with increased disease risk (unpublished findings).
Although none of the SNPs in LINGO2 were found to associate with PD after correction for
multiple testing, nominal significant P values were observed. Given the high degree of
homology between the LINGO1 and LINGO2 proteins (61%), and recently reported
association studies, both LINGO1 and its paralog LINGO2 are reasonable candidate genes
for ET and PD.
In the present study, we examine the role of LINGO1 and LINGO2 in ET and PD by
sequencing both genes in a series of patients with ET (n=95) and PD (n=96), and by
performing association studies in ET and PD patient-control series (combined n=2,522)
using tagging SNPs (tSNPs) that capture >95% of the genetic variability of LINGO1 and
LINGO2. We identified ten rare coding variants (nine novel) in LINGO1 and LINGO2; three
of them did not segregate with disease within families. However, we found evidence
suggesting LINGO1 and LINGO2 variation influences risk for and onset age of ET and PD,
expanding the scope of genetic factors common to both diseases.
Methods
Study population
A total of 1,247 patients with ET, 633 patients with PD, and 642 control subjects of
Caucasian origin from North America were included in this study (Mayo Clinic
Jacksonville: 150 ET, 438 PD, and 423 controls; Emory University: 214 ET, 195 PD, and
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219 controls; Columbia University: 449 ET; Baylor College of Medicine: 228 ET; and
University of Saskatchewan: 206 ET). The control groups consisted of unrelated individuals
and spouses free of known neurological disease. Demographics for each group are given in
Table 1. All patients were examined by a movement disorders neurologist and diagnosed
with PD according to published criteria [23] or satisfied clinical criteria for definite or
probable ET [24]. All sites obtained local ethics committee approval prior to subject
enrollment. Individuals were informed of all aspects pertaining to their participation in the
study and gave either written or proxy consent.
DNA sequencing of LINGO1 and LINGO2
Genomic DNA was extracted from peripheral blood lymphocytes using standard protocols.
Primer pairs for LINGO1 and LINGO2 (available on request) were used to sequence all
coding exons and exon–intron boundaries by polymerase chain reaction (PCR) in 95
randomly selected ET and 96 PD probands from the Mayo Clinic Jacksonville. PCR
products were purified from unincorporated nucleotides using Agencourt bead technology
(Beverly, MA, USA) with Biomek FX automation (Beckman Coulter, Fullerton, CA, USA).
Sequence analysis was performed as previously described [25]. All novel variants were
examined for disease segregation when possible in affected and unaffected family members
by additional sequencing.
Genetic association analysis
The population frequency of six known coding variants with minor allele frequency (MAF)
<10% and six novel LINGO1 and three LINGO2 variants was assessed in the case-control
series. Selection of additional tSNPs was based on HapMap Phase II data using Haploview
software [26]. The regions containing LINGO1 and LINGO2 exons from any reported
transcript (±2.5 kb surrounding noncoding exons or ±10 kb for coding exons) were used for
the selection of tSNPs. In total 16 tSNPs across LINGO1 and 21 across LINGO2 loci were
selected to capture >95% of the polymorphic variation in these regions (MAF>5% and
r2>0.8) in Caucasian population standards. Genotyping of tSNPs and of known and novel
coding variants (MAF<10%), identified by sequencing, was performed on a Sequenom
MassArray iPLEX platform (San Diego, CA, USA); all primer sequences are available on
request. For each variant genotyping error was assessed by deviation from Hardy–Weinberg
equilibrium expectation. All genotypes are given on the “+” strand.
Associations for PD and ET were evaluated using logistic regression models adjusted for
age and gender; odds ratios (ORs) and 95% confidence intervals (CIs) were estimated.
Single SNP associations with age at disease onset were examined using linear regression
models adjusted for gender; regression coefficients and 95% CIs were estimated. Due to the
alternate association findings in previous reports, both dominant (major allele homozygote
vs minor allele homozygote and heterozygote) and recessive (minor allele homozygote vs
major allele homozygote and heterozygote) models were considered in all regression
analyses. P values<0.05 were considered significant, and no adjustment for multiple testing
was performed in this exploratory study.
Results
Sequencing analysis in 95 ET and 96 PD patients identified six novel coding variants in
LINGO1 (Ser4Cys, Val107Met, Ala277Thr, Arg423Arg, Gly537Ala, and Asp610Asp) and
three in LINGO2 (Asp135Asp, Pro217Pro, and Val565Val; Fig. 1, Table 2). In addition five
known polymorphisms were detected in LINGO1 (rs2271398, rs2271397, rs2271396,
rs3743481, and rs61737308), four of which with a MAF>10%. Three novel variants in
LINGO1 (Ser4Cys, Val107Met, and Gly537Ala) did not segregate with disease within
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families (Fig. 2); two of these variants, Ser4Cys and Gly537Ala, as well as Ala277Thr,
Arg423Arg, and Asp610Asp in LINGO1 and Pro217Pro and Arg507His in LINGO2 were
observed exclusively in cases and not in controls (Table 2).
Results of single SNP associations with ET and PD are presented in Table 3. Whereas the
original report and one replication study identified the minor allele of rs9652490 associated
with an increased risk of ET [19, 20], we previously identified association with ET and PD
for the major allele [9]. The association study of LINGO1 tSNPs identified only the
previously reported variant (rs9652490) being associated with both ET and PD under a
recessive model (ET, OR=0.63, P=0.026; PD, OR=0.54, P=0.016). The risk allele found to
be overrepresented in the disease groups was the major allele (T; genotype frequencies are
provided in Supplemental Table 1). This association is consistent with our previous report
[9] but in disagreement with other studies [19, 20]. The reasons for this alternate association
are unclear, but several theoretical hypothesis have been proposed [27].
Additional associations with ET were identified for rs4886887, rs3144, rs8028808, and
rs12905478 (Table 3), spanning the entire LINGO1 gene (Fig. 1). Similarly to the previously
described association with rs9652490, the major alleles of rs8028808 and rs12905478 were
overrepresented in cases resulting in protective ORs for the minor alleles (OR=0.49 and
0.36, respectively). However, for rs4883887 and rs3144, the associations were driven by the
minor alleles (OR=1.83 and 1.48, respectively). No additional tSNPs in LINGO1 were found
to be significantly associated with PD. The analysis of LINGO2 tSNPs in ET resulted in
only one variant (rs1412229) being associated with disease under a recessive model
(OR=0.72, P=0.015). Similar results were obtained for rs10968280 and PD under a
dominant model (OR=0.73, P=0.029; Table 3).
One variant in LINGO1 (rs907396) was associated with a 5-year younger mean age at ET
onset (P=0.019). Association with the age of PD onset identified two variants conferring a
later age at onset by approximately 5 years when the minor allele was present in
homozygote form (rs4886887, P=0.047; rs3144, P=0.024; Supplemental Table 2). An
earlier age at onset for ET by 4 to 5 years was also observed for two variants in LINGO2
(rs10812774 and rs7033345). In contrast, none of the variants in LINGO2 were significantly
associated with age at onset of PD, however a trend toward an association (0.05≤P≤0.07)
was observed for four variants (rs9644872, rs11793421, rs4879257, and rs6476092;
Supplemental Table 2).
Discussion
Progress in the field of neurodegenerative disorders has highlighted the interplay of
combined genetic factors in determining risk for complex traits. While variability in several
genes may influence the risk for developing one disease, single genes often affect the risk
for more than one trait. This diversity is best exemplified by variability in the tau (MAPT)
and α-synuclein (SNCA) genes which alters risk of PD (MAPT and SNCA), progressive
supranuclear palsy and corticobasal degeneration (MAPT), and multiple system atrophy
(SNCA) [28–31]. However, while a growing number of genes have been implicated in both
sporadic and familial PD, genetic factors in ET have remained elusive [9, 32]. The LINGO1
SNP rs9652490 was recently shown to associate with ET, a finding that was replicated
independently and extended to PD [9, 19, 20]. Taken together with the established role of
LINGO1 in neuronal survival and the preliminary evidence implicating LINGO2 in PD,
these data support LINGO1 and LINGO2 as candidate genes for ET and PD. In the present
study, we examined this hypothesis by performing a comprehensive evaluation of both
genes in a multicenter series of North American patients with ET and PD and in control
subjects. The sequencing effort identified six novel coding mutations in LINGO1 and three
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in LINGO2. However, three of these variants did not display segregation with disease in
three families including a multi-incident kindred with PD and ET. Identification of
additional families will be required to examine segregation and assess pathogenicity of the
other six novel variants. Although all nine novel variants were rare (MAF≤0.16%), six of
them were found only in patients and not in control subjects, indicating a possible role in
pathogenesis that warrants further studies. Interestingly, three of the six variants found only
in patients were identified in both ET and in PD, which supports the notion that genetic
factors may influence both diseases simultaneously.
The association study using tSNPs identified one variant in LINGO1 which alters the risk for
both ET and PD (rs9652490), consistent with our previous report [9]. Interestingly, there is a
discrepancy between the results of our two studies and those of others in which the
association with disease was driven by the minor allele of rs9652490 [19, 20]. Possible
explanations include population-specific differences, although the largest series used in the
replication part of the initial report was ethnically similar to our patient-control series (US
Caucasians) [19]. Four additional variants in LINGO1 and one in LINGO2 influenced the
risk of ET, and one SNP in LINGO2 altered the risk of PD. Furthermore, five variants in
LINGO1 and LINGO2 had an effect on age at onset in ET (three variants) and PD (two
variants). Despite the fact that these associations would not have withstood adjustment for
the number of statistical tests performed and should therefore be considered exploratory,
several lines of evidence are supportive including that: (1) LINGO1 is biologically plausible
as a candidate gene for neurodegenerative disease; (2) this is the fourth study by three
independent groups in Caucasian and Asian populations that consistently nominate variants
in LINGO1 as a risk factor for developing ET; and (3) variants which display evidence of
association with disease span the entire LINGO1 gene. Factors contributing to our results not
withstanding correction for multiple testing may include diagnostic inaccuracy (known to
occur in both ET and PD), or the use of genetically heterogeneous, admixed North American
populations. Power is unlikely to have played a major role as our combined ET series is the
largest studied so far and our PD population is adequately powered to detect associations
within the range of expected magnitude. Assuming a disease prevalence of 1%, an allele
frequency of 0.25, and an OR of 2, we have >99% power to detect a dominant and 84% for a
recessive association in our ET case-control study and a >99% dominant and 72% recessive
association in PD.
A better molecular understanding of the pathogenesis for two prevalent movement disorders
(ET and PD) will play a significant part in designing future therapeutic strategies aimed at
prevention and cure. The results or our study support a role for LINGO1 and LINGO2 in
determining risk for and onset age of ET and PD. Further replication studies on large and
ethnically diverse populations are warranted to confirm these findings and to pave the way
for the functional work that will unravel the pathogenic mechanisms involved.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Schematic representation of the LINGO1 (top) and LINGO2 (bottom) genes indicating the
exons (boxes) and the variants studied. Novel (above the genes) and known (below the
genes) coding variants are given in bold. For LINGO1 exon arrangement was based on the
two transcripts BC068558 and BC011057. The position of the start codon (ATG) was
determined according to BC011057
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Fig. 2.
Segregation analysis of three novel coding LINGO1 variants in three pedigrees, representing
males as squares, females as circles, whereas a number inside a symbol indicates the
number of additional siblings. Patients with PD have right-half-dark-filled symbols, patients
with ET have left-half-dark-filled symbols, deceased individuals are indicated with a
diagonal line, and probands with an arrow head
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Table 1
Demographic characteristics of patients and controls
Controls Essential tremor Parkinson disease
No. of patients 642 1,247 633
Age 73±10 (33–101) 67±15 (9–97) 71±11 (30–92)
Male gender (n, %) 310 (48%) 530 (43%) 359 (57%)
Age at disease onset N/A 50±20 (4–88) 62±12 (16–85)
The sample mean ± SD (range) is given for age and age at disease onset. Age at disease onset was only available in 396 ET and 423 PD cases
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Table 2
Minor allelic counts and frequency for LINGO1 and LINGO2 coding variants
rs/ss number Amino acid change Controls Essential tremor Parkinson disease
LINGO1
 ss179321698 S4C 0 1 (0.04%) 1 (0.08%)
 ss179321700 V107M 1 (0.08%) 1 (0.04%) 0
 rs9855 S183F 0 0 0
 ss179321701 A277T 0 2 (0.08%) 1 (0.08%)
 rs34904447 S295S 0 0 0
 rs61737308 P370P 18 (1.40%) 46 (1.84%) 21 (1.66%)
 ss179321703 R423R 0 1 (0.04%) 0
 rs61737307 P519P 0 0 0
 rs11853548 P525P 0 0 0
 ss179321704 G537A 0 3 (0.12%) 1 (0.08%)
 ss179321705 D610D 0 2 (0.08%) 0
LINGO2
 ss179321693 D135D 3 (0.23%) 2 (0.08%) 2 (0.16%)
 ss179321694 P217P 0 1 (0.04%) 0
 rs17506843 R507H 0 2 (0.08%) 0
 ss179321696 V565V 1 (0.08%) 1 (0.04%) 1 (0.08%)
Only those variants with a minor allele frequency over 10% were analyzed in this study
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